Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan

Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in JapanReal-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan, Published online: 29 August 2018; doi:10.1038/s41433-018-0192-2Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan

Source: Eye - August 29, 2018 Category: Opthalmology Authors: Kyoko Ohno-Matsui Makoto Suzaki Rie Teshima Nina Okami Source Type: research